Oxford BioMedica (UK) Limited

About Oxford BioMedica (UK) Limited

Oxford BioMedica (UK) Limited is a leading gene and cell therapy company based in the United Kingdom, renowned for its innovative approach to developing advanced therapies for serious diseases. The company specializes in the development of viral vector-based therapies, particularly focusing on the use of lentiviral vectors to deliver genetic material into cells.

With a strong commitment to research and development, Oxford BioMedica aims to transform the treatment landscape for conditions such as cancer, neurodegenerative diseases, and rare genetic disorders. The company collaborates with various pharmaceutical and biotechnology partners to advance its therapeutic candidates through clinical trials and into commercialisation.

Oxford BioMedica’s state-of-the-art manufacturing facilities are equipped to produce high-quality viral vectors at scale, ensuring that they meet the stringent regulatory requirements necessary for clinical and commercial use. The company’s expertise in process development and manufacturing has positioned it as a trusted partner in the biopharmaceutical industry.

In addition to its core activities, Oxford BioMedica is dedicated to fostering innovation and advancing scientific knowledge in the field of gene and cell therapy. The company actively participates in collaborations with academic institutions and research organizations to drive forward the next generation of therapeutic solutions.

As part of its vision, Oxford BioMedica strives to make a significant impact on patient lives by providing effective and accessible therapies. The company is committed to maintaining the highest standards of quality and safety in all its operations, ensuring that patients receive the best possible care.

Through its ongoing dedication to excellence and innovation, Oxford BioMedica (UK) Limited continues to be at the forefront of the gene and cell therapy revolution, paving the way for new treatment options that have the potential to change the lives of patients around the world.